Raymond James reiterates Strong Buy on Taysha Gene Therapies stock

Raymond James reiterated a Strong Buy and $13 price target on Taysha (TSHA) vs current share price $4.58 (market cap $1.25B), citing FDA feedback and confidence in filing on 6-month REVEAL Part B data; it expects Part B 6-month data by end-2026, a BLA filing in H1 2027 and approval/launch in Q4 2027. The firm projects revenues of $92.2M, $284.0M, $545.6M and $846.1M for fiscal 2027-2030, while InvestingPro warns the stock may be overvalued despite a 143% 1-year return. Taysha reported FY2025 net loss $109.0M (-$0.34/sh) vs $89.3M (-$0.36) the prior year, underscoring ongoing cash burn and pipeline execution risk.

Analysis

Current market pricing for TSHA embeds a material probability of a successful regulatory and commercial outcome; that implies investors are paying a premium for binary clinical/regulatory readouts and a narrow orphan-market penetration. Because treatment economics in small-patient rare diseases are highly levered to patient-identification and pricing, modest changes to penetration assumptions (±500 patients or ±$200k/year pricing) swing peak-sales multiples by severalx, magnifying post-data moves.

A key second-order bottleneck is supply-chain and manufacturing cadence for AAV-based programs: even with positive clinical data, CDMO slot constraints and yield variability can delay commercialization by quarters and compress near-term realized revenue versus modeled peak sales. Payer access is another nonlinear risk — accelerated approvals in rare disease often trigger protracted HTA/payer negotiations that cap uptake for 12–36 months even after label clearance.

Tail risks include a single adverse safety signal or FDA request for additional bridging data, each capable of wiping out >50% of equity value in weeks; conversely, clear supportive bridging feedback would re-rate the equity quickly. The most actionable hedge is volatility: implied vol is likely elevated around upcoming readouts, creating asymmetric option trades where limited-cost long-dated structures capture upside while defined-loss short-term spreads monetize premium.

For allocators, size and time-horizon matter: a 12–24 month oriented sleeve can justify concentrated exposure via LEAP structures funded by short biotech beta, while tactical traders should prefer defined-risk, event-tied spreads to avoid open-ended dilution and regulatory binary risk.

Key Decisions for Investors

• Long-dated directional: Buy TSHA Jan 2028 LEAP 5–15 call spread (buy lower strike, sell higher strike) sized to 1–2% NAV. Rationale: captures multi-quarter approval optionality with defined downside; target 3x upside if favorable regulatory progress, max loss = premium paid.
• Event hedge pair: Long TSHA equity (0.5–1% NAV) paired with short XBI (0.5% NAV) to neutralize sector beta ahead of pivotal readouts over the next 6–18 months. Rationale: isolates idiosyncratic outcome while limiting market-wide biotech drawdowns; reduce long if implied vol compresses post-data.
• Volatility play (tactical): Buy TSHA 9–12 month ATM straddle or long call with 30–40% notional, funded by selling a near-term OTM call spread 30–60 days post-readout. Rationale: capture large move on binary outcome, monetize expected short-term vol mean-reversion after event.
• Downside protection: Buy a 6–12 month TSHA put spread (OTM) sized to offset 30–50% of long exposure. Rationale: limits drawdown from adverse safety/regulatory asks while keeping upside participation.
• Supply-chain long (satellite): Allocate 0.5% NAV to select AAV/CDMO equities (or ETF exposure) to capture upside from accelerated manufacturing demand if gene-therapy commercial timelines accelerate. Rationale: benefits from fill-rate and pricing power independent of single-product clinical outcomes.